Lamond David

Average Profitability
<0.0001%
Insider Buys Quantity
14
Insider Buys Sum
$601,547.46
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Lamond David

According to the SEC Form 4 filings, Lamond David, being in a position of

  1. director at Quince Therapeutics, Inc.,
    оver the last 12 months, has bought 168384 shares for $167,913, and sold 0 shares,
    over all time since 2023-08-15, has bought 500436 shares for $601,547, and sold 0 shares.

The largest purchase of all time was on 2023-08-16 and amounted to 117348 shares of Quince Therapeutics, Inc. for $151,379.

Biography of Lamond David

No biography is available at this moment.

2023-12-14PurchaseQuince Therapeutics, Inc.
QNCX
director
22,627
0.0528%
$1.04$23,532-4.81%
2023-12-13PurchaseQuince Therapeutics, Inc.
QNCX
director
22,627
0.0528%
$1.00$22,627-0.97%
2023-12-12PurchaseQuince Therapeutics, Inc.
QNCX
director
22,627
0.0544%
$1.02$23,074-0.68%
2023-12-07PurchaseQuince Therapeutics, Inc.
QNCX
director
19,123
0.0446%
$1.01$19,314-1.4%
2023-12-06PurchaseQuince Therapeutics, Inc.
QNCX
director
19,123
0.0455%
$1.02$19,505-0.38%
2023-12-05PurchaseQuince Therapeutics, Inc.
QNCX
director
19,123
0.0466%
$1.01$19,314+1.48%
2023-12-01PurchaseQuince Therapeutics, Inc.
QNCX
director
14,378
0.033%
$0.94$13,515+4.44%
2023-11-30PurchaseQuince Therapeutics, Inc.
QNCX
director
14,378
0.035%
$0.90$12,940+15.19%
2023-11-29PurchaseQuince Therapeutics, Inc.
QNCX
director
14,378
0.035%
$0.98$14,090+5.31%
2023-08-31PurchaseQuince Therapeutics, Inc.
QNCX
director
41,026
0.1136%
$1.32$54,154-21.37%
2023-08-30PurchaseQuince Therapeutics, Inc.
QNCX
director
41,026
0.1145%
$1.31$53,744-19.77%
2023-08-17PurchaseQuince Therapeutics, Inc.
QNCX
director
24,766
0.0684%
$1.29$31,948-17.32%
2023-08-16PurchaseQuince Therapeutics, Inc.
QNCX
director
117,348
0.323%
$1.29$151,379-18.22%
2023-08-15PurchaseQuince Therapeutics, Inc.
QNCX
director
107,886
0.3087%
$1.32$142,410-16.54%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.